Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 3 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.

Featured Broker Partners


Advertisement